Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology

Spinal Puncture Clinical Trial

Official title:

Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00775112
• Other study ID #: Lumbar puncture pillow
• Status: Completed
• Phase: N/A
• First received: October 16, 2008
• Last updated: October 16, 2008
• Start date: July 2004

Study information

• Verified date: October 2008
• Source: Centre Leon Berard
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

We have developed a positioning cushion for LP which allows the child to be relaxed in an adequate position, and to maintain this position throughout LP. This study was aimed at evaluating the benefit of the device on the technical quality of LPs, on pain, anxiety, post LP syndrome, and on the satisfaction of children, their parents and caregivers.

The study was a two-centre, open, randomized trial, with two parallel groups. Children aged 2 to 18 years undergoing a LP were eligible, if not included in the study before. Those who had used the cushion before, with a medical reason preventing the use of the cushion, those refusing or whose parents refused could not be included. Randomization was stratified by centre.

Four cushion sizes were available for the age ranges: 2-6 years, 6-10 years, 10-15 and 15-18 years. The primary outcome was the rate of success, defined as a LP reaching its objective at the first attempt, without hemorrhage (visible hemorrhage or RBC > 50/mm3 in the CSF sample). Secondary outcomes included: the child's pain using a visual analogic scale (VAS), parents and caregiver perception of the child's pain (VAS); the children, parents, caregiver and physician performing the LP satisfaction; children cooperation using the "Le Baron Scale", and the occurrence of a post LP syndrome.

Description:

Our study was an open, randomized, controlled trial, with two parallel groups assigned to "LP pillow" or "no intervention" conducted in patients undergoing LP.

Participants Children aged 2 to 18 years undergoing an LP were eligible for inclusion. Children who had already participated or used the LP pillow, who had a medical condition (orthopaedic anomaly) contraindicating the use of the LP pillow or whose parents refused consent were excluded.

A permuted-block algorithm was used for randomization, with participants stratified according to centre. Concealed allocation was achieved by a phone call to the coordination centre after eligibility check and baseline data collection.

Intervention The LP pillow was made of polyethylene microcellular foam, coated with rubber to facilitate decontamination. It was placed on the thighs of the child sitting with the trunk leaning forward. This position ensures maximum lumbar flexion whereas resting the trunk on the pillow allows relaxation of paravertebral muscles. The axis of the body and the spinal column were maintained perfectly symmetrical in the sagittal plane (see illustration Fig 1).

The pillow included side supports for the head; the face remained uncovered so that the child could breathe and speak comfortably; this also facilitated nitrous oxide administration. Props supporting the patient's arms maintained the cervical column in a neutral position. An opening allowed touching the child's hands and forearms. Splints at the bottom side immobilized the child's thighs to ensure effective stabilization.

Four sizes were available corresponding approximately to the following age ranges: 2-6 years, 6-10 years, 10-15 and 15-18 years. Two sets were available for the study, one per centre.

Outcomes Primary outcome was the technical quality of the LP, classified as success or failure. A successful LP is defined as one that achieves its purpose (sampling and/or treatment) at the first attempt, without visible haemorrhage and with RBC < 50/mm3 in the cerebrospinal fluid (CSF) sample (biochemical analysis).

Secondary outcomes included: child's pain, evaluated by self-administered visual analogical scales (VAS) for children over 6 years of age; parents' and caregivers' perception of the child's pain; satisfaction of the children, parents, caregivers and physician performing the LP assessed using verbal scoring; child cooperation rated with the "LeBaron Scale" (Lebaron 1984). Other outcomes included the number of attending persons (parents and/ or caregivers); duration of positioning and procedure; incidence, symptoms and duration of post-LP syndrome assessed 48 hours after LP by phone interview.

Data collection included anaesthetic, sedative and analgesic drugs used; needle size (19G, 20G, 22G); general status of the child evaluated with Karnofsky or Lansky score (Lansky 1985); platelet count; number of previous LP; date of and satisfaction with the last LP (verbal scale), practitioner experience in performing LP, presence of the parents, aim of the LP: diagnosis, therapeutic monitoring, treatment injection; amount of CSF removed (drops).

The study protocol was approved by the institutional review board of Lyon A - Hôtel-Dieu on June 8th 2004, and was conducted in accordance with the Helsinki Declaration. All parents gave written informed consent before participation of their child. Children were asked to give written consent when fully able to understand the proposed procedure.

Data were managed using CLININFO S.A. (France) software and services for clinical trial data management and quality control.

Sample size and statistical analysis The protocol initially included a total of 80 children. The sample size calculation was based on a rate of success of 70% in the control group and 95% in the pillow group, with 80%-power and 0.05 two-sided significance level (N Query® software). Based on the rate of success in the control group after inclusion of the 40th child, the sample size was re-estimated and increased to 124 children (62 per group) and the inclusion period was extended from 12 to 24 months. Comparisons between groups were performed using non parametric methods, i.e. the Wilcoxon rank test or the Fisher's exact test, depending on the nature of the variable. A logistic regression model was fitted to the platelet count and the number of LP prior to entering the study. An exploratory subgroup analysis was performed in children over 6 years of age. Comparisons with p-value less than 0.05 were considered significant. The STATA 9.2 (SatatCorp 2005. Stata Statistical Software: Release 9.0 College Station, TX: Satat Corporation) software was used to perform statistical analyses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. primary completion date: September 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria:

• Children aged 2 to 18 years undergoing an LP

Exclusion Criteria:

• Children who had already participated or used the LP pillow

• medical condition (orthopaedic anomaly) contraindicating the use of the LP pillow

• Parents refusal

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Spinal Puncture

Intervention

Device:
• pillow
use of pillow for lumbar punctures

Locations

Country	Name	City	State
France	centre Leon Berard	Lyon
France	Hopital Debrousse	Lyon

Sponsors (2)

Lead Sponsor	Collaborator
Centre Leon Berard	Hopital Debrousse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	technical quality of the LP, classified as success or failure.		immediate	No
Secondary	child's pain		immediate	No
Secondary	satisfaction of the children, parents, caregivers and physician performing the LP assessed using verbal scoring;		immediate	No
Secondary	number of attending persons		immediate	No
Secondary	symptoms and duration of post-LP syndrome assessed 48 hours after LP		48 hours	No